Retatrutide 10 mg (1 Vial) – Hilma Biocare

Description

Retatrutide – Hilma Biocare

Retatrutide (LY3437943) by Hilma Biocare is a next-generation triple receptor agonist that simultaneously activates GLP-1, GIP, and Glucagon receptors — making it the most powerful peptide currently available for weight loss and metabolic control. Unlike Semaglutide (single agonist) or Tirzepatide (dual agonist), Retatrutide targets all three key metabolic pathways at once.

Retatrutide is a 39-amino-acid synthetic peptide derived from a GIP backbone, engineered with a C20 fatty diacid moiety for albumin binding and extended half-life of approximately 6 days, enabling convenient once-weekly dosing.

In Phase 2 clinical trials (NEJM, 2023), Retatrutide demonstrated up to 24% reduction in body weight at 48 weeks — the highest weight loss efficacy ever recorded for any peptide therapy.

Key Benefits

🔥 Unmatched Fat Loss — up to 24% body weight reduction in clinical trials
⚡ Triple Receptor Action — GLP-1 + GIP + Glucagon simultaneously
🍽 Appetite Suppression — reduces hunger and caloric intake
💊 Glycemic Control — lowers HbA1c and fasting blood glucose
🔋 Increased Energy Expenditure — glucagon receptor activation boosts metabolic rate
❤️ Cardiovascular Benefits — improves lipid profile and reduces visceral fat
📅 Once-Weekly Injection — long half-life (~6 days) for easy compliance

Mechanism of Action

Retatrutide works through three complementary pathways:

• GLP-1 receptor: Reduces appetite, slows gastric emptying, enhances insulin secretion
• GIP receptor: Potentiates insulin response, improves fat metabolism (8.9× more potent than endogenous GIP)
• Glucagon receptor: Increases energy expenditure and fat oxidation, preventing metabolic adaptation during weight loss

Dosage Protocol (Titration)

Administer subcutaneously once weekly. Gradual titration is essential to minimize GI side effects:

Weeks 1–4: 2 mg/week
Weeks 5–8: 4 mg/week
Weeks 9–12: 6–8 mg/week
Maintenance: 8–12 mg/week (based on individual response)

Reconstitution: Add 1–2 ml bacteriostatic water. Store reconstituted vial at 2–8°C, use within 4 weeks.

Comparison vs Other GLP-1 Peptides

Side Effects

Most common (dose-dependent, usually transient): nausea, diarrhea, vomiting, constipation, decreased appetite. Recommended to start at low dose and titrate slowly to minimize GI discomfort.

Contraindications

History of medullary thyroid cancer or ME